Pravastatin sodium

SKU: orb1310398

Description

Pravastatin sodium

Research Area

Cell Biology, Metabolism Research

Key Properties

• CAS Number: 81131-70-6
• MW: 446.52
• Purity: 99.97%
• Formula: C₂₃H₃₅NaO₇
• SMILES: [C@H]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(=O)[O-])OC(=O)[C@@H](C)CC.[Na+]
• Target: Ferroptosis,Autophagy,HMG-CoA Reductase
• Solubility: DMSO:247.5 mg/mL (554.29 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.48 mM);H2O:44.7 mg/mL (100.11 mM)

Bioactivity

• Target IC50:
  HMG-CoA reductase:5.6 μM
• In Vivo:
  In murine peritoneal macrophages (MPM) the J-774 A.1 macrophage-like cell line, and human monocyte-derived macrophages (HMDM), Pravastatin exhibits a dose-dependent Inhibition of cholesterol synthesis. Upon LDL addition, concentration of Pravastatin below 0.19 μg mL enhanc the esterification of cellular cholesterol, whereas levels below 100 μg mL suppress esterification. At less than 0.5 mM, Pravastatin attenuate the Rho/ROCK pathway activity in human ileal and colonic transplants, reducing CCN2 mRNA levels. Pravastatin at concentration less than 1 mM also induce the Inhibition of CCN2 in Primary human smooth musclee cells. In All cases, Pravastatin at less than 0.5 mM reduce the mRNA levels of type I collagen and fibronectin. Pravastatin facilitates vasodilation in aortic rings, achieving 62.8% endothelium-dependent relaxation at 10 μM after 8 minutes. Pravastatin-Na at 10 μM inhibits sterol synthesis with 50% greater efficacy than in peripheral blood mononuclear cells. In bovine aortic endothelial cells, Pravastatin at less than 10 μM stimulates NOS activity and NO release within 10 minutes, with L-arginine further enhancing NO production in response to Pravastatin.
• In Vitro:
  Pravastatin (30 mg/kg/day) reduced malnutrition-induced lesions by 34%. In f Male Wistar rats exposed to radiation, which presented with decreased CCN2 levels, Pravastatin (30 mg/kg/day) could restore musclee structure. a single dose of 40 mg of Pravastatin lowered cholesterol synthesis by 62% in monocytes from healthy individuals and by 47% in patients with hypercholesterolemia. Moreover, treatment with Pravastatin (40 mg/day for 8 weeks) in hypercholesterolemic patients increased LDL degradation by 57% while inhibiting cholesterol synthesis by 55%.

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Pravastatin sodium, Pravastatin, Inhibitor, HMG-CoA Reductase (HMGCR), HMGCoAReductase, HMG-CoA reductase, HMGCoA Reductase, HMGCR, Ferroptosis, inhibit, CS 514, CS514, CS-514, CS-514 (sodium), CS-514 Sodium, Autophagy

Compound Identifiers

PubChem CID

16759173